ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Ophthalmology · Am J Ophthalmol · 2026-07-25

Model-based cost-effectiveness analysis (secondary analysis of LIGHTSITE III data) in intermediate dry AMD: photobiomodulation vs no treatment gave a base-case ICER of $73,910/QALY over 10 years, below US thresholds; 5-year US budget impact $25.0 billion at 20% uptake.

Secondary analysis
Watane et al. Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial
Ophthalmology · Ophthalmol Retina · 2026-06-03

In 198 people aged ≥60 with geographic atrophy, oral gildeuretinol acetate did not significantly slow 24-month lesion growth vs placebo (1.62 vs 1.87 mm²/yr; P=0.075). Exploratory visual function outcomes favoured gildeuretinol (nominal P values only).

RCTn = 198
Boyer et al. Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.